2018 AANS Annual Scientific Meeting-582. Treatment of traumatic brain injury with vepoloxamer (purified Poloxamer 188) improves functional recovery in rats

582. Treatment of traumatic brain injury with vepoloxamer (purified Poloxamer 188) improves functional recovery in rats

Video Transcription

Video Summary

The video transcript discusses a study conducted by Asim Mahmood on the treatment of traumatic brain injury (TBI) with a drug called Vipaloximer. The study was conducted in collaboration with LifeRef Technologies, who provided the drug. TBI is a significant issue, with millions of hospital visits, deaths, and long-term morbidity cases. Currently, treatment options are limited to removing brain lesions and providing optimal care in the ICU. However, Vipaloximer, an FDA-approved tri-block polypolymer, has shown promise in reducing TBI-induced damage by sealing membranes, reducing brain edema, and improving mitochondrial function. The study used a controlled cortical impact model and observed positive results in terms of tissue recovery, functional improvement, reduced inflammation, and normalized bleeding time. The drug shows therapeutic potential for TBI but further clinical studies are necessary.

Asset Caption

Asim Mahmood, MD, FAANS

Keywords

Asim Mahmood

traumatic brain injury

Vipaloximer

LifeRef Technologies

TBI treatment